WO1996020732A3 - Non-traumatic administration of gene delivery vehicles - Google Patents

Non-traumatic administration of gene delivery vehicles Download PDF

Info

Publication number
WO1996020732A3
WO1996020732A3 PCT/US1995/016967 US9516967W WO9620732A3 WO 1996020732 A3 WO1996020732 A3 WO 1996020732A3 US 9516967 W US9516967 W US 9516967W WO 9620732 A3 WO9620732 A3 WO 9620732A3
Authority
WO
WIPO (PCT)
Prior art keywords
administration
gene delivery
delivery vehicles
traumatic
gdvs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1995/016967
Other languages
French (fr)
Other versions
WO1996020732A2 (en
WO1996020732A9 (en
Inventor
Elizabeth S Song
Kieron J Kowal
Douglas J Jolly
Dominic Montisano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Viagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Viagene Inc filed Critical Chiron Viagene Inc
Priority to JP8521148A priority Critical patent/JPH10512243A/en
Priority to EP95944671A priority patent/EP0800403A2/en
Priority to AU47431/96A priority patent/AU4743196A/en
Publication of WO1996020732A2 publication Critical patent/WO1996020732A2/en
Publication of WO1996020732A9 publication Critical patent/WO1996020732A9/en
Publication of WO1996020732A3 publication Critical patent/WO1996020732A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The non-traumatic administration of one or more gene delivery vehicles ('GDVs') to an animal. Such non-traumatic administration provides significant advantages over prior methods of administration because it does not require any injection or other invasion of the recipient, and therefore is much less injurious to the recipient. Further, because there is no injection or invasion, there is typically less need for highly skilled personnel to administer the GDVs, there is less need for sterile conditions, and there is less risk of infection, injury and other side effects.
PCT/US1995/016967 1994-12-30 1995-12-20 Non-traumatic administration of gene delivery vehicles Ceased WO1996020732A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP8521148A JPH10512243A (en) 1994-12-30 1995-12-20 Non-traumatic administration of gene delivery vehicles
EP95944671A EP0800403A2 (en) 1994-12-30 1995-12-20 Non-traumatic administration of gene delivery vehicles
AU47431/96A AU4743196A (en) 1994-12-30 1995-12-20 Non-traumatic administration of gene delivery vehicles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36678894A 1994-12-30 1994-12-30
US08/366,788 1994-12-30

Publications (3)

Publication Number Publication Date
WO1996020732A2 WO1996020732A2 (en) 1996-07-11
WO1996020732A9 WO1996020732A9 (en) 1996-09-12
WO1996020732A3 true WO1996020732A3 (en) 1996-12-12

Family

ID=23444505

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/016967 Ceased WO1996020732A2 (en) 1994-12-30 1995-12-20 Non-traumatic administration of gene delivery vehicles

Country Status (4)

Country Link
EP (1) EP0800403A2 (en)
JP (1) JPH10512243A (en)
AU (1) AU4743196A (en)
WO (1) WO1996020732A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US7282364B2 (en) 2001-08-31 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7348177B2 (en) 1998-12-31 2008-03-25 Novartis Vaccines And Diagnostics, Inc. Expression of HIV polypeptides and production of virus-like particles

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5695993A (en) 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
ZA973642B (en) 1996-04-26 1997-11-25 Merck & Co Inc DNA vaccine formulations.
US5945100A (en) * 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
WO1998008539A1 (en) * 1996-08-26 1998-03-05 Chiron Corporation Postinfection human immunodeficiency virus (hiv) vaccination therapy
JP2001500738A (en) * 1996-09-17 2001-01-23 カイロン コーポレイション Compositions and methods for treating intracellular diseases
US6096303A (en) * 1997-07-31 2000-08-01 Medical College Of Georgia Research Institute, Inc. Method to enhance treatment of cystic tumors
EP0967288A1 (en) * 1998-06-16 1999-12-29 Hoechst Marion Roussel Deutschland GmbH Transfection system for the transfer of nucleic acids into cells
EP0908521A1 (en) * 1997-10-10 1999-04-14 Hoechst Marion Roussel Deutschland GmbH Transfection system for the transfer of nucleic acids into cells
WO1999019502A1 (en) * 1997-10-10 1999-04-22 Aventis Pharma Deutschland Gmbh Transfection system for the transfer of nucleic acids into cells
WO1999031262A2 (en) * 1997-12-16 1999-06-24 Valentis, Inc. Needle-free injection of formulated nucleic acid molecules
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
DE10010959A1 (en) 2000-03-06 2001-09-20 Eppendorf Geraetebau Netheler Process for transferring material in a cell system
WO2002063026A1 (en) * 2001-02-08 2002-08-15 Geneporter, Inc. Complexes and components thereof for introducing polynucleotides into eukaryotic cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003769A1 (en) * 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
EP0586076A2 (en) * 1992-08-07 1994-03-09 American Home Products Corporation Recombinant adenovirus vaccines
WO1994023582A1 (en) * 1993-04-08 1994-10-27 Genetic Therapy, Inc. Adenoviral vectors including dna encoding lung surfactant protein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003769A1 (en) * 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
EP0586076A2 (en) * 1992-08-07 1994-03-09 American Home Products Corporation Recombinant adenovirus vaccines
WO1994023582A1 (en) * 1993-04-08 1994-10-27 Genetic Therapy, Inc. Adenoviral vectors including dna encoding lung surfactant protein

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348177B2 (en) 1998-12-31 2008-03-25 Novartis Vaccines And Diagnostics, Inc. Expression of HIV polypeptides and production of virus-like particles
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US9598469B2 (en) 2001-07-05 2017-03-21 Novartis Vaccines And Diagnostics, Inc. HIV-1 south african subtype C env proteins
US7282364B2 (en) 2001-08-31 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof

Also Published As

Publication number Publication date
WO1996020732A2 (en) 1996-07-11
AU4743196A (en) 1996-07-24
EP0800403A2 (en) 1997-10-15
JPH10512243A (en) 1998-11-24

Similar Documents

Publication Publication Date Title
WO1996020732A3 (en) Non-traumatic administration of gene delivery vehicles
EP1238677A3 (en) Parenteral fat emulsions comprising edetate as preservative
AU693073B2 (en) Systems and methods for communicating with ambulatory medical devices such as drug delivery devices
DE69535349D1 (en) An implantable active medical device having means for discriminating between resting and active states of the patient
AU8933391A (en) Medical drug formulation and delivery system
AU608264B2 (en) Delivery vehicles with amphiphile-associated active ingredient
AU8046691A (en) Drug delivery system involving interaction between protein or polypeptide and hydrophobic biodegradable polymer
WO1994001147A3 (en) Administration of medicaments to poultry
EP1262206A3 (en) Patient specific dosing contrast media delivery systems
DE69333607D1 (en) Device for the production of pre-filled, sterile delivery devices
AU3127697A (en) Intravenous catheter and delivery system
DE59510531D1 (en) Container for the storage and administration of injection, infusion and diagnostic preparations
BR9707637A (en) Implantable implant system intended for subcutaneous or local administration and pharmaceutical set
FR08C0001I2 (en)
AU5673399A (en) Compositions and methods for treating intracellular infections
NZ234802A (en) Long acting injectable formulations comprising an avermectin compound and triacetin. treatment for internal and external parasites of animals
ITVI920062A0 (en) FILTER ASSEMBLY, PARTICULARLY FOR MEDICAL INFUSION AND TRANSFUSION LINES
IL107153A (en) Pharmaceutical compositions for preventing insulin-dependent diabetes mellitus comprising IL10 and method for their manufacture
DE69935526D1 (en) SUPRAMOLECULAR COMPLEX-CONTAINING MEDICAMENTS
AU5745494A (en) Pre-filled, sterilized syringe and method of making
AU5643299A (en) Humic acid and its use in the treatment of various conditions
CA2159485A1 (en) Anti-oxydant alkylaryl polyether alcohol polymers
EP0373388A3 (en) Penem derivatives and process for their preparation
James AIDS research" spin-off"--ganciclovir CMV prevention after liver transplantation
FR2701213B3 (en) Injection cannula for medical treatment.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/18-11/18 AND 14/18-18/18,DRAWINGS,REPLACED BY NEW PAGES 1/19-11/19 AND 14/19-19/19;PAGES 12/18 AND 13/18,RENUMBERED AS PAGES 12/19 AND 13/19;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 1995944671

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995944671

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1995944671

Country of ref document: EP